Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
July 10 2024 - 8:00AM
Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical
stage biopharmaceutical company focused on developing novel
therapeutics to address unmet medical needs in liver and viral
diseases, today announced that it will host a virtual KOL event
featuring Mark Sulkowski, MD, Johns Hopkins University School of
Medicine, to discuss the unmet need and current treatment landscape
for patients with chronic hepatitis B (CHB), positive data from the
Phase 1b study of ALG-000184, development plans, and the chronic
suppression regulatory pathway on Thursday, July 18, 2024 at 3:00pm
ET/12:00pm PT.
“We are pleased to be hosting this KOL event with Dr. Sulkowski,
as we are excited to share the recent FDA feedback on the path
forward to bring our best/first-in-class molecule to patients in
need of better therapies,” stated Lawrence Blatt, Ph.D., MBA,
Chairman, President, and Chief Executive Officer at Aligos
Therapeutics. “ALG-000184 monotherapy continues to show
unprecedented reductions in all viral markers of CHB without viral
breakthrough, with data 72 weeks that was recently presented
at the EASL Congress 2024. The efficacy data to date has already
demonstrated the potential for superiority compared to
nucleos(t)ide analogs, reducing HBV DNA levels below 10 IU/mL in
both HBeAg-positive and HBeAg-negative patients at Week 48. We look
forward to providing additional details on the chronic suppression
indication during the event.”
Mark Sulkowski, MD, is a Professor of Medicine, the Senior
Associate Dean for Clinical Trials, and the Founding Director of
the Office of Clinical Trials at the Johns Hopkins University
School of Medicine. He also serves as the Director of the Division
of Infectious Diseases at the Johns Hopkins Bayview Medical Center,
a Deputy Director for the Johns Hopkins Institute for Clinical and
Translational Research, and the Medical Director of the Viral
Hepatitis Center in the Divisions of Infectious Diseases and
Gastroenterology/Hepatology in the Department of Medicine. He
received his MD from Temple University School of Medicine,
Philadelphia, PA, pursued training in Internal Medicine at Duke
University School of Medicine, Durham, NC, and completed his
Fellowship in Infectious Diseases at the Johns Hopkins University
School of Medicine.
To register for the KOL event, please click
here. All attendees are required to register in advance
for the webcast. For those who are unable to attend live, a replay
will be available by clicking here.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical
company that was founded in 2018 with the mission to become a world
leader in the treatment of liver and viral diseases. Aligos’
strategy is to harness the deep expertise and decades of drug
development experience its team has in liver and viral diseases to
discover and develop potentially best-in-class therapeutics for
metabolic dysfunction-associated steatohepatitis (MASH) and viruses
with high unmet medical need such as hepatitis B and
coronaviruses.
For more information, please visit www.aligos.com or follow us
on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this press release that are not historical
facts may be considered “forward-looking statements,” including
without limitation, statements regarding Aligos’ financial results
and performance as well as research and development activities,
including regulatory status and the timing of announcements and
updates relating to our regulatory filings and clinical trials.
Such forward-looking statements are subject to substantial risks
and uncertainties that could cause our development programs, future
results, performance, or achievements to differ materially from
those anticipated in the forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
inherent in the drug development process, including Aligos’
clinical-stage of development, the process of designing and
conducting clinical trials, the regulatory approval processes, and
other matters that could affect the sufficiency of Aligos’ capital
resources to fund operations. For a further description of the
risks and uncertainties that could cause actual results to differ
from those anticipated in these forward-looking statements, as well
as risks relating to the business of Aligos in general, see Aligos’
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on May 7, 2024 and its future periodic reports
to be filed or submitted with the Securities and Exchange
Commission. Except as required by law, Aligos undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances, or to reflect the occurrence
of unanticipated events.
Investor ContactJordyn TaraziVice President,
Investor Relations & Corporate Communications+1 (650)
910-0427jtarazi@aligos.com
Media ContactMichael FitzhughLifeSci
Communicationsmfitzhugh@lifescicomms.com
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Jul 2023 to Jul 2024